Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

The effects of admission hyperglycemia and diabetes mellitus on mechanical thrombectomy outcomes: A systematic review and meta-analysis
Bilgin, Gokce Belge , Bilgin, Cem , Jabal, Mohamed Sobhi , Kobeissi, Hassan , Ghozy, Sherief , Şenol, Yiğit Can , Orscelik, Atakan , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Belge Bilgin, Gokce , Ghozy, Sherief , Kobeissi, Hassan , Orscelik, Atakan , Senol, Yigit Can , Bilgin, Cem , Rabinstein, Alejandro A.

Interventional Neuroradiology | January 17, 2025 | Volume: 32 | Issue: 4 | Pages: 1831-1842

10.1177/15910199241306774 | PMID 39819212 Get It

Background The impact of certain comorbidities on mechanical thrombectomy (MT) outcomes remains largely unexplored. Diabetes mellitus (DM) and admission hyperglycemia have been associated with poor clinical outcomes for patients treated with MT. In this study, we sought to investigate the effects of DM and admission hyperglycemia on MT outcomes. Methods Following PRISMA guidelines, a systematic literature search was conducted in Medline, Embase, Scopus, and Web of Science databases. Data regarding successful recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] ≥2b), functional independence (modified Rankin Scale [mRS] 0–2), excellent outcomes (mRS 0–1), symptomatic intracranial hemorrhage (sICH), and mortality were extracted from the included studies. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated using random effects model. Results Twenty-one studies comprising 9708 patients were included. A total of 2311 patients (24%) had a history of DM, and 2026 patients (21%) had admission hyperglycemia. Admission hyperglycemia was associated with significantly lower odds of mTICI ≥2b (OR = 0.7, 95% CI = 0.55–0.89), mRS 0–2 (OR = 0.47, 95% CI = 0.41–0.53), and mRS 0–1 (OR = 0.43, 95% CI = 0.34–0.55) as compared to normoglycemic state. Patients with hyperglycemia had significantly higher rates of sICH (OR = 2.05, 95% CI = 1.66–2.54) and mortality (OR = 1.99, 95% CI = 1.58–2.52) than normoglycemic patients. Diabetes mellitus was associated with significantly high rates of mortality (OR = 1.74, 95% CI = 1.31–2.3) and lower rates of mRS 0–2 (OR = 0.60, 95% CI = 0.48–0.76) in sensitivity analyses. Conclusion Our results indicate that admission blood glucose levels and DM can negatively affect MT outcomes. Further research should focus on optimizing MT outcomes for these patients.
Factors Influencing the Choice Between Multi-Target Stool DNA and Colonoscopy for Colorectal Cancer Screening Among Alaska Native Peoples
Jeffries, Lauren , Flanagan, Christie A. , Kisiel, John B. , Redwood, Diana , Kisiel, John B , Redwood, Diana G , Flanagan, Christie , Jeffries, Lauren A., Rutten, Lila J. Finney

Life | January 17, 2025 | Volume: 15 | Issue: 1 | Pages: 120

10.3390/life15010120 | PMID 39860060 Get It

The Alaska Tribal Health System is increasing colorectal cancer (CRC) screening among Alaska Native (AN) peoples, who experience the highest CRC rate in the world. Through a clinical trial (NCT04336397), AN people living in rural/remote Alaska were offered either the previously unavailable multi-target stool DNA test (mt-sDNA; Cologuard®) or colonoscopy. From April 2022 to August 2024, 113 (59%) people who completed mt-sDNA testing and 51 (39%) who completed a colonoscopy procedure participated in a survey on factors influencing their screening test choice. The majority of mt-sDNA participants (79%) were aware of the colonoscopy option, while most colonoscopy participants (72%) reported being unaware of the mt-sDNA option. Key mt-sDNA preference themes included not having to travel, less time commitment, childcare and work responsibilities, physical limitations, greater convenience, and the test being less invasive and dangerous than a colonoscopy. In contrast, colonoscopy preference themes included wanting to adhere to screening recommendations, be proactive about preventative health, family history of cancer, awareness of the higher CRC risk among AN peoples, as well as the belief that colonoscopy is more reliable and accurate since it is performed by medical providers. These findings underscore the complex factors influencing CRC screening preferences among rural and remote AN people. Limited access to medical facilities, financial burdens, and personal commitments, along with personal factors, have a substantial bearing on the screening decision-making process. Recognizing and addressing these multifaceted influences can help CRC screening programs better meet community member needs and preferences, ultimately improving screening rates and colorectal health outcomes.
INSIDE-OUT: Introduction of Speakers at IDWeek Events—Observing for Unconscious Bias Over Time
Marcelin, Jasmine R , Lyden, Elizabeth , Abdul‐Mutakabbir, Jacinda C. , Kullar, Ravina , Ristagno, Elizabeth H. , Time), the INSIDE-OUT Study Group (Introduction of Speakers at IDWeek Events—Observing for Unconscious Bias Over, Rajapakse, Nipunie , Patel, Megha, Miller, Amy M. , Oeltjen, Erin N, Semaj, Sophie, Sramek, Kyle T, Lindeman, Christopher J, Daubach, Eric C., Akinmoladun, Oladapo O, Wurtz, Paul J, Ristagno, Elizabeth H , Marcelin, Jasmine , Khazanchi, Rohan , Cawcutt, Kelly , Ha, David R , Florez, Narjust , Time), the INSIDE-OUT Study Group (Introduction of Speakers at IDWeek Events—Observing for Unconscious Bias Over, Patel, Megha, Akinmoladun, Oladapo O., Yang, Yuhong

Open Forum Infectious Diseases | January 17, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1093/ofid/ofaf024 | PMID 39963695 Get It

Abstract Background Specialty societies, including the Infectious Diseases Society of America, strive to address gender and racial inequities in professional advancement. Microaggressions remain a persistent and pervasive barrier to these goals. Nonprofessional speaker introductions are a manifestation of race- and gender-based microaggressions, which have not been previously assessed at IDWeek. We assessed disparities in speaker introductions at IDWeek over a 7-year period that included formal gender equity initiatives introduced in 2016. Methods We conducted a retrospective observational study of video-recorded IDWeek speaker introductions from 2013 to 2019. Trained coders reviewed presentation video archives to assess a primary outcome of nonprofessional introductions: when a speaker's professional title was not used as the first introduction. We used descriptive statistics, Fisher exact tests, Cochrane-Armitage trend tests, and multivariable logistic regression to characterize relationships between speaker introductions and presentation year, speaker demographics, and speaker-moderator demographic concordance. Results Of 1940 videos reviewed, 48.9% of IDWeek speakers received nonprofessional introductions during and before 2016 vs 41.5% of speakers after 2016 (P = .0013). There was an increasing linear trend in the frequency of professional introductions by speaker age group from 47.1% for age <40 years to 65.3% for age >60 years (P < .0001). White moderators more frequently used nonprofessional introductions than moderators from backgrounds underrepresented in medicine (47.7% vs 29.1%, P = .0014). Women-men speaker-moderator pairs had more nonprofessional introductions (54.6%, P < .001). Conclusions In the largest assessment of microaggressions in speaker introductions at a national medical specialty conference, we highlighted some progress over time and ample opportunity to further standardize equitable speaker introductions, especially for women and junior speakers
White matter hyperintensities and TDP‐43 pathology in Alzheimer's disease
Carlos, Arenn F. , Weigand, Stephen D. , Pham, Nha Trang Thu, Petersen, Ronald C. , Jack, Clifford R. , Whitwell, Jennifer L. , Josephs, Keith A. , Jack, Clifford R , Carlos, Arenn F , Dickson, Dennis W.

Alzheimer's & Dementia | January 17, 2025 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14516 | PMID 39821594 Get It

Abstract INTRODUCTION Greater white matter hyperintensities (WMHs) on magnetic resonance imaging (MRI) are seen with transactive response DNA‐binding protein 43 (TDP‐43) pathology in frontotemporal lobar degeneration (FTLD‐TDP). WMH associations with TDP‐43 pathology in Alzheimer's disease (AD‐TDP) remain unclear. METHODS A total of 157 participants from Mayo Clinic Rochester with autopsy‐confirmed AD, known TDP‐43 status, and antemortem fluid‐attenuated inversion recovery (FLAIR) MRI were included. Vascular risk factors were assessed. A semi‐automated WMH segmentation‐quantification process produced total and regional WMH volumes. Penalized linear regression models adjusting for age at MRI analyzed TDP‐43 associations (status and typing) with WMHs. RESULTS TDP‐43‐positive status was not associated with WMH burden overall because opposite effects were seen based on AD‐TDP typing. Despite similar antemortem vascular risk factors and postmortem vascular pathologies, AD‐TDP type‐ α showed greater total and regional WMH burden (particularly in subcortical frontotemporal and basal ganglia regions) than TDP‐43 negatives and AD‐TDP type‐ β . DISCUSSION AD‐TDP types may have different WMH pathomechanisms, with type‐ α having associations more like FTLD‐TDP than AD. Highlights In transactive response DNA‐binding protein 43 (TDP‐43) pathology in Alzheimer's disease (AD‐TDP), TDP‐43 status alone is not associated with total or regional WMH burden AD‐TDP type‐ α shows greater total, frontotemporal subcortical, and basal ganglia white matter hyperintensities (WMHs) AD‐TDP type‐ β shows less total and subcortical occipital WMHs AD‐TDP type‐ α effect on WMH burden closely mimics the effects of frontotemporal lobar degeneration with TDP‐43 (FTLD‐TDP) rather than AD Different relationships of AD‐TDP types with WMHs suggest different pathomechanisms
Reconstruction of a Through-and-Through Auricular Defect With Full-Thickness Loss of the Postauricular Scalp
Lohman, Mary E. , Demer, Addison M. , O'Hern, Keegan , O’Hern, Keegan

Dermatologic Surgery | January 17, 2025 | Volume: 52 | Issue: 3 | Pages: 279-281

10.1097/dss.0000000000004549 | PMID 39819802 Get It

Treatment options to break the cycle of recurrent pericarditis
Raisinghani, Ajit, Luis, Sushil Allen

Current Opinion in Cardiology | January 17, 2025 | Volume: 40 | Issue: 2 | Pages: 107-114

10.1097/hco.0000000000001201 | PMID 39819644 Get It

Purpose of review This review provides a contemporary, evidence-based update on the pathophysiological mechanisms and rapidly evolving therapeutic options for recurrent pericarditis. Recent findings Recent studies have elucidated the pathogenesis of recurrent pericarditis, identifying autoinflammation as a key mechanism and interleukin-1 (IL-1) as a central modulator of the inflammatory cascade. Multiple clinical trials have investigated novel therapeutic approaches, particularly focusing on IL-1 inhibition. The recent FDA approval of IL-1 pathway blockade for recurrent pericarditis has revolutionized treatment, offering patients significantly improved quality of life and symptom management. Summary The enhanced understanding of the autoinflammatory nature of recurrent pericarditis, coupled with groundbreaking advances in targeted therapies, has transformed the treatment landscape for affected patients. The emergence of IL-1 inhibitors as an effective therapeutic option promises substantial improvements in clinical outcomes and patient well being. Clinicians must familiarize themselves with these new treatments, their efficacy, and potential limitations to optimize patient care and guide therapeutic decision-making in this challenging condition.
VaxBot-HPV: a GPT-based chatbot for answering HPV vaccine-related questions
Li, Yiming , Li, Jianfu , Li, Manqi , Yu, Evan , Rhee, Danniel , Tang, Lu , Cui, Licong , Tao, Cui, Tang, Lu , Cui, Licong , Li, Yiming , Amith, Muhammad , Savas, Lara S.

JAMIA Open | January 17, 2025 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/jamiaopen/ooaf005 | PMID 39975811 Get It

Abstract Objective Human Papillomavirus (HPV) vaccine is an effective measure to prevent and control the diseases caused by HPV. However, widespread misinformation and vaccine hesitancy remain significant barriers to its uptake. This study focuses on the development of VaxBot-HPV, a chatbot aimed at improving health literacy and promoting vaccination uptake by providing information and answering questions about the HPV vaccine. Methods We constructed the knowledge base (KB) for VaxBot-HPV, which consists of 451 documents from biomedical literature and web sources on the HPV vaccine. We extracted 202 question-answer pairs from the KB and 39 questions generated by GPT-4 for training and testing purposes. To comprehensively understand the capabilities and potential of GPT-based chatbots, 3 models were involved in this study: GPT-3.5, VaxBot-HPV, and GPT-4. The evaluation criteria included answer relevancy and faithfulness. Results VaxBot-HPV demonstrated superior performance in answer relevancy and faithfulness compared to baselines. For test questions in KB, it achieved an answer relevancy score of 0.85 and a faithfulness score of 0.97. Similarly, it attained scores of 0.85 for answer relevancy and 0.96 for faithfulness on GPT-generated questions. Discussion VaxBot-HPV demonstrates the effectiveness of fine-tuned large language models in healthcare, outperforming generic GPT models in accuracy and relevance. Fine-tuning mitigates hallucinations and misinformation, ensuring reliable information on HPV vaccination while allowing dynamic and tailored responses. The specific fine-tuning, which includes context in addition to question-answer pairs, enables VaxBot-HPV to provide explanations and reasoning behind its answers, enhancing transparency and user trust. Conclusions This study underscores the importance of leveraging large language models and fine-tuning techniques in the development of chatbots for healthcare applications, with implications for improving medical education and public health communication.
Bone Enzyme-Responsive Biodegradable Poly(propylene fumarate) and Polycaprolactone Polyphosphoester Dendrimer Cross-Linked via Click Chemistry for Bone Tissue Engineering
Liu, Xifeng , Schreiber, Areonna , Potes, Maria Astudillo , Dashtdar, Babak , Rezaei, Asghar , Elder, Benjamin D. , Lu, Lichun , Schreiber, Areonna C , Astudillo Potes, Maria D, Lu, Lichun , Hamouda, Abdelrahman M.

Biomacromolecules | January 17, 2025 | Volume: 26 | Issue: 2 | Pages: 835-847

10.1021/acs.biomac.4c00999 | PMID 39818811 Get It

Characterization of Human Senescent Cell Biomarkers for Clinical Trials
Monroe, David G. , Atkinson, Elizabeth J. , Froemming, Mitchell N. , Ruan, Ming, LeBrasseur, Nathan K. , Khosla, Sundeep , Monroe, David G , LeBrasseur, Nathan K , Khosla, Sundeep , Farr, Joshua N.

Aging Cell | January 17, 2025 | Volume: 24 | Issue: 5 | Pages: No page available

10.1111/acel.14489 | PMID 39823170 Get It

ABSTRACT There is an increasing need for biomarkers of senescent cell burden to facilitate the selection of participants for clinical trials. p16 Ink4a is encoded by the CDKN2A locus, which produces five variant transcripts in humans, two of which encode homologous p16 proteins: p16 Inka4a , encoded by p16_variant 1 , and p16ɣ, encoded by p16_variant 5. While distinct quantitative polymerase chain reaction primers can be designed for p16_variant 5, primers for p16_variant 1 also measure p16_variant 5 ( p16_variant 1 + 5 ). In a recent clinical trial evaluating the effects of the senolytic combination, dasatinib + quercetin (D + Q), on bone metabolism in postmenopausal women, we found that women in the highest tertile for T‐cell expression of p16_variant 5 had the most robust skeletal responses to D + Q. Importantly, the assessment of p16_variant 5 was more predictive of these responses than p16_variant 1 + 5 . Here, we demonstrate that in vitro, p16_variant 1 + 5 increased rapidly (Week 1) following the induction of DNA damage, whereas p16_variant 5 increased later (Week 4), suggesting that p16_variant 5 becomes detectable only when the abundance of senescent cells reaches some threshold. Further analysis identified a SASP panel in plasma that performed as well in identifying postmenopausal women with a positive skeletal response to D + Q. Collectively, our findings provide further support for the T‐cell p16_variant 5 assay as a biomarker for selecting participants in clinical trials of senolytic interventions. In addition, our data indicate that correlated plasma SASP markers could be used in lieu of the more technically challenging T‐cell p16 assay. Trial Registration: ClinicalTrials.gov identifier: NCT04313634.